Search research articles
Contact Us
Filters
Showing results (51-60 of 55) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 55 results.
JTO Clinical and Research Reports
|
April 14, 2025
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
Yoko Tsukita, Rei Umezawa, Taku Nakagawa, et al.
Internal Medicine (Tokyo, Japan)
|
July 19, 2017
An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a
Yuichi Yamazaki, Aya Suzuki, Kimitoshi Hirayanagi, et al.
The Oncologist
|
February 28, 2013
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901
Toshiyuki Harada, Satoshi Oizumi, Kenichiro Ito, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2025
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study
Hiromi Nagashima, Tatsuro Fukuhara, Yu Utsumi, et al.
Cancer Science
|
May 4, 2023
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial
Kazutaka Fujita, Ryo Arai, Satoshi Shoji, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 55) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 55 results.
JTO Clinical and Research Reports
|
April 14, 2025
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902
Yoko Tsukita, Rei Umezawa, Taku Nakagawa, et al.
Internal Medicine (Tokyo, Japan)
|
July 19, 2017
An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a
Yuichi Yamazaki, Aya Suzuki, Kimitoshi Hirayanagi, et al.
The Oncologist
|
February 28, 2013
A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901
Toshiyuki Harada, Satoshi Oizumi, Kenichiro Ito, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2025
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study
Hiromi Nagashima, Tatsuro Fukuhara, Yu Utsumi, et al.
Cancer Science
|
May 4, 2023
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial
Kazutaka Fujita, Ryo Arai, Satoshi Shoji, et al.
Page
of 6